UPDATE 2-Biotech company CureVac aims to raise up to $245 mln in U.S. IPO [Reuters]
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
US:NYSE Investor Relations:
gsk.com/en-gb/investors
Company Research
Source: Reuters
CureVac aims to raise up to $245 million in U.S. IPO FRANKFURT (Reuters) - CureVac, one of Germany’s leading contenders to develop a COVID-19 vaccine, said it aims to raise up to $245 million in an initial public stock offering (IPO) on the U.S. Nasdaq. The biotech firm said on Monday it plans to offer a total of up to 15.33 million new shares, adding the shares will likely be priced at between $14.00 and $16.00 apiece. Bank of America, Jefferies and Credit Suisse are acting as joint book-runners, with Berenberg and Kempen & Co acting as passive book-running managers, it added. The proceeds will fund the development of an mRNA-based COVID-19 vaccine, the ramp-up of manufacturing capabilities, its oncology drug development and the development of a rabies vaccine, among other ventures, according to the statement. The group, which is controlled by Software firm SAP co-founder Dietmar Hopp and also backed by the foundation of Microsoft co-founder Bill Gates, initially flagged plans to go
Show less
Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GSK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GSK alerts
High impacting GSK plc American Depositary Shares (Each representing two Ordinary Shares) news events
Weekly update
A roundup of the hottest topics
GSK
News
- BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 MillionGlobeNewswire
- GSK Trades At Low Price Multiples, But Its Pipeline Needs To Improve [Seeking Alpha]Seeking Alpha
- 12 Best Biotech Penny Stocks to Invest In [Yahoo! Finance]Yahoo! Finance
- Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancerBusiness Wire
- GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising RiseBusiness Wire
GSK
Sec Filings
- 5/8/24 - Form 6-K
- 5/8/24 - Form 6-K
- 5/3/24 - Form 6-K
- GSK's page on the SEC website